Featured Research

from universities, journals, and other organizations

Wnt Signaling Key in Rare Skin Disease

Date:
January 22, 2010
Source:
American Journal of Pathology
Summary:
Researchers have discovered that Wnt signaling is involved in the development of pachydermoperiostosis.

Dr. Kenji Kabashima and colleagues at the Kyoto University Graduate School of Medicine have discovered that Wnt signaling is involved in the development of pachydermoperiostosis. They present these findings in the February 2010 issue of The American Journal of Pathology.

Pachydermoperiostosis is a rare skin disease characterized by pachydermia (skin thickening), digital clubbing, and periostosis (abnormal bone deposits) of long bones. Fibroblasts help to form the structural framework for various tissues, including the skin and bones, and therefore likely play a role in this process.

As the Wnt signaling pathway plays a developmental role in both bone and skin, Kabashima et al hypothesized that Wnt signaling was involved in the development of pachydermia. They found that DKK1, a Wnt-signaling antagonist, was expressed at lower levels in pachydermoperiostosis than in control fibroblasts, whereas the Wnt-signaling molecule β-catenin was expressed at higher levels. In addition, expression of DKK1 inhibited fibroblast proliferation, and DKK1-inhibition increased skin thickening in mouse ears. Therefore, enhanced Wnt signaling may contribute to pachydermia by increasing levels of fibroblast proliferation.

Dr. Kabashima and colleagues therefore conclude that "enhanced Wnt signaling is related to the development of pachydermia."


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kabashima K, Sakabe J-i, Yoshiki R, Tabata Y, Kohno K, Tokura Y. Involvement of Wnt Signaling in Dermal Fibroblasts. American Journal Of Pathology, 2009; DOI: 10.2353/ajpath.2010.090454

Cite This Page:

American Journal of Pathology. "Wnt Signaling Key in Rare Skin Disease." ScienceDaily. ScienceDaily, 22 January 2010. <www.sciencedaily.com/releases/2010/01/100122002838.htm>.
American Journal of Pathology. (2010, January 22). Wnt Signaling Key in Rare Skin Disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/01/100122002838.htm
American Journal of Pathology. "Wnt Signaling Key in Rare Skin Disease." ScienceDaily. www.sciencedaily.com/releases/2010/01/100122002838.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins